Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases

Bioorg Med Chem Lett. 2014 Jan 15;24(2):520-5. doi: 10.1016/j.bmcl.2013.12.036. Epub 2013 Dec 16.

Abstract

Several five- and six-membered heterocycles were introduced to replace the C2-position amide bond of the original 2-aminothiazole-based hit compound 5. Specifically, replacement of the amide bond with an imidazolidinone moiety yielded a novel and potent thiazolylimidazolidinone series of SCD1 inhibitors. XEN723 (compound 22) was identified after optimization of the thiazolylimidazolidinone series. This compound demonstrated a 560-fold improvement in in vitro potency and reduced plasma desaturation indices in a dose dependent manner, with an EC50 of 4.5 mg/kg.

Keywords: Amide bioisosteres; Desaturation index; SCD1 inhibitors; Stearoyl-CoA desaturase-1; Thiazolylimidazolidinone.

MeSH terms

  • Amides / chemistry*
  • Amides / pharmacology
  • Amides / therapeutic use
  • Animals
  • Dose-Response Relationship, Drug
  • Drug Discovery / methods*
  • Drug Evaluation, Preclinical / methods
  • Enzyme Inhibitors / chemistry
  • Enzyme Inhibitors / pharmacology
  • Enzyme Inhibitors / therapeutic use
  • Female
  • Hep G2 Cells
  • Humans
  • Imidazolidines / chemistry*
  • Imidazolidines / pharmacology
  • Imidazolidines / therapeutic use
  • Metabolic Diseases* / drug therapy
  • Metabolic Diseases* / enzymology
  • Mice
  • Rats
  • Rats, Sprague-Dawley
  • Stearoyl-CoA Desaturase / antagonists & inhibitors*
  • Stearoyl-CoA Desaturase / metabolism

Substances

  • Amides
  • Enzyme Inhibitors
  • Imidazolidines
  • Scd1 protein, mouse
  • Stearoyl-CoA Desaturase